ECTS Abstracts (2015) 1 P330

Low bone mineral density and comorbidities in patients with rheumatoid arthritis

I Dydykina1, E Vetkova1, M Podvorotova1, E Taskina1, A Smirnov1, A Sinenko2, T Ruskina3, D Peshekhonov4, S Myasoedova5, B Zavodovski6, P Dydykina1, E Petrova1, O Alekseeva1, L Alekseeva1 & E Nasonov1

1Nasonova Research Institute of Rheumatology, Moscow, Russia; 2Regional Clinical Hospital of Vladivostok, Vladivostok, Russia; 3Medical University “Kemerovo State Medical Institute” Russian Ministry of Health, Kemerovo, Russia; 4Medical University “Voronezh State Medical Academy named after Burdenko”, Voronezh, Russia; 5Medical University “Ivanovo State Medical Academy” of the Ministry of Health of the Russian Federation, Ivanovo, Russia; 6Research Experimental Institute of Rheumatology, Russian Academy of Medical Sciences, Volgograd, Russia.

It’s known, the rate and extent of bone loss in RA can be influenced by various factors associated both with the RA and other diseases. The purpose was to study influence of common comorbidities on prevalence of osteoporosis (OP) in patients with RA in clinical practice. Through of the national program we analysed data of Dual-energy X-ray absorptiometry (DXA) in lumbar spine, femoral neck and forearm on 691 patients. Two groups of patients were formed: with and without OP 196 (28%) and 495 (72%), respectively. In both groups, the number of women prevailed, the average age of 60,9±2,8 in group 1, 56,1±2,1 in group 2[p>0,05]. 81% and 69% women had menopause, respectively [p<0,05]. The average duration of RA was 17±2,1 years, 15,4±7,1, respectively [p <0,05]. 51% and 41% of patients had one or more comorbidities, respectively [p<0,05]. To select the high risk group of OP and fractures among patients with RA in clinical practice should keep in mind such factors as age, menopause, duration of RA and comorbidities.

Group with OPGroup without OP
22% EP1 (87% TD2, 11% diabetes type 2)15% EP1 (79% TD2, 19% diabetes type 2)
66% CVD3 (64% H4, 26% CHD5, 2% 6MI, 8% stroke)49% CVD3 (77% of H4, 19% CHD5, 2% 6MI, 2% stroke)
14% RP7 (57% COPD8, 14% asthma, 4% tuberculosis, 4% sarcoidosis, 21% PF9)14% RP7 (80% COPD8, 12% asthma, 4% tuberculosis, 4% PF9)
27% GIP10(38% SU/DU11, 36% CG12, 2% cirrhosis, 2% GERD13, 5% VH14, 2% GSD15)27% GIP10 (35% SU/DU11, 45% CG12, 1% GERD13, 1% VH14)
1endocrinologocal pathology, 2thyroid disease, 3cardiovascular disease, 4hypertension, 5 coronary heart disease, 6myocardial infarction, 7respiratory pathology, 8chronic obstructive pulmonary disease, 9pulmonary fibrosis, 10gastrointestinal pathology, 11stomach/duodenal ulcer, 12chronic gastritis, 13gastroesophageal-reflux disease, 14viral hepatitis, 15gallstone disease.

Disclosure: The authors declared no competing interests.